TY - JOUR
T1 - Real-World Trends in Intravitreal Injection Practices among American Retina Specialists
AU - Chaturvedi, R.
AU - Wannamaker, Kendall W.
AU - Riviere, Paul J.
AU - Khanani, Arshad M.
AU - Wykoff, Charles C.
AU - Chao, Daniel L.
N1 - Funding Information:
Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (D.L.C.); and the BrightFocus Foundation, Clarksburg, Maryland (D.L.C.). Financial Disclosure(s): The author(s) have made the following disclosure(s): P.J.R.: Financial support ? Peptide Logic, LLC. C.W.C.: Consultant ? Bayer, PolyPhotonix, RecensMedical, Kodiak, Alimera Sciences, Allegro, Alnylam, DORC, Notal Vision, ONL Therapeutics, Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, Genentech/Roche; Financial support ? Adverum, Neurotech, Opthea, Samsung, Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, Genentech/Roche. D.L.C.: Consultant ? Recens Medical, Allergan; Advisory board ? DTX Pharma, Zilia Health; Research funding ? Opthea, Clearside Biomedical. Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (D.L.C.); and the BrightFocus Foundation, Clarksburg, Maryland (D.L.C.). Obtained funding: N/A The authors thank all of the participating retina specialists for taking time to answer this online survey. They also thank Dr. Dorota Skowronska Krawczyk for advice and use of computers for this study. Financial Disclosure(s): The author(s) have made the following disclosure(s): P.J.R.: Financial support ? Peptide Logic, LLC. C.W.C.: Consultant ? Bayer, PolyPhotonix, RecensMedical, Kodiak, Alimera Sciences, Allegro, Alnylam, DORC, Notal Vision, ONL Therapeutics, Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, Genentech/Roche; Financial support ? Adverum, Neurotech, Opthea, Samsung, Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, Genentech/Roche. D.L.C.: Consultant ? Recens Medical, Allergan; Advisory board ? DTX Pharma, Zilia Health; Research funding ? Opthea, Clearside Biomedical. Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (D.L.C.); and the BrightFocus Foundation, Clarksburg, Maryland (D.L.C.). Obtained funding: N/A
Publisher Copyright:
© 2019 American Academy of Ophthalmology
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Purpose: To analyze practice patterns used for intravitreal injections (IVIs) by retinal specialists in the United States. Design: Cross-sectional online survey. Participants: Retina specialists in the United States who responded to a web-based survey. Methods: Retinal specialists in the United States were contacted via e-mail to complete a web-based, anonymous, 24-question survey. Multivariate analysis was performed on a selected question of interest focused on choice of anesthetic used for IVI. Main Outcome Measures: Differences in IVI practices, such as antibiotic preferences, and different odds of anesthetic use by demographic variables with 95% confidence intervals. Results: A total of 281 retinal specialists responded to the survey (17% response rate). Respondents’ average age was 53 years, with an average of 20 years in practice. Respondents practiced in 42 states, with 90% practicing in an urban or suburban area. For anesthesia, 14% used a topical anesthetic with cotton swab compression, 27% used a subconjunctival anesthetic, and 31% used an anesthetic gel. Age, gender, geographic location, and practice setting did not seem to impact choice of anesthetic for IVI significantly. Sixty-six percent of respondents always use a lid speculum, 21% administer topical antibiotics before injection, 36% wear a mask, 73% wear gloves, and 45% always dilate the eyes before injection. Most respondents use a 30-gauge needle and inject in the inferior temporal quadrant (70%). Forty-five percent always perform bilateral injections the same day if indicated. After the injection, 14% administer post operative nonsteroidal anti-inflammatory drugs, 28% administer postoperative antibiotics, and 31% routinely check intraocular pressure after injection. Conclusions: This study provided real-world trends in practices for IVI among retina specialists in the United States. In addition, age, gender, practice type, and geographic location did not influence anesthetic choice for IVI.
AB - Purpose: To analyze practice patterns used for intravitreal injections (IVIs) by retinal specialists in the United States. Design: Cross-sectional online survey. Participants: Retina specialists in the United States who responded to a web-based survey. Methods: Retinal specialists in the United States were contacted via e-mail to complete a web-based, anonymous, 24-question survey. Multivariate analysis was performed on a selected question of interest focused on choice of anesthetic used for IVI. Main Outcome Measures: Differences in IVI practices, such as antibiotic preferences, and different odds of anesthetic use by demographic variables with 95% confidence intervals. Results: A total of 281 retinal specialists responded to the survey (17% response rate). Respondents’ average age was 53 years, with an average of 20 years in practice. Respondents practiced in 42 states, with 90% practicing in an urban or suburban area. For anesthesia, 14% used a topical anesthetic with cotton swab compression, 27% used a subconjunctival anesthetic, and 31% used an anesthetic gel. Age, gender, geographic location, and practice setting did not seem to impact choice of anesthetic for IVI significantly. Sixty-six percent of respondents always use a lid speculum, 21% administer topical antibiotics before injection, 36% wear a mask, 73% wear gloves, and 45% always dilate the eyes before injection. Most respondents use a 30-gauge needle and inject in the inferior temporal quadrant (70%). Forty-five percent always perform bilateral injections the same day if indicated. After the injection, 14% administer post operative nonsteroidal anti-inflammatory drugs, 28% administer postoperative antibiotics, and 31% routinely check intraocular pressure after injection. Conclusions: This study provided real-world trends in practices for IVI among retina specialists in the United States. In addition, age, gender, practice type, and geographic location did not influence anesthetic choice for IVI.
UR - http://www.scopus.com/inward/record.url?scp=85069888630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069888630&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2019.03.023
DO - 10.1016/j.oret.2019.03.023
M3 - Article
AN - SCOPUS:85069888630
SN - 2468-6530
VL - 3
SP - 656
EP - 662
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 8
ER -